The guests of the special edition of the Patient Week are: prof. Konrad Rejdak, president of the Polish Neurological Society and Malina Wieczorek, president of the SM-Walcz o Siebie Foundation.
Tydzień Pacjencki
What are the expected changes in the treatment of multiple sclerosis?
Published April 22, 2022 11:45
In the conversation we asked about this:
- what are the benefits of subcutaneous administration? In the drug program B.46, in the second line, natalizumab is used - a drug with proven effectiveness and safety. Now it has appeared in a different form of administration: subcutaneous administration.
- what are the benefits for the health care system of introducing this form of administration?
- consequences of the pandemic in the context of MS treatment: the number of patients entering the drug program has decreased due to the spread of COVID-19.
- what to do to effectively treat war refugees from Ukraine, including MS patients, and not burden the medical staff at the same time? If you add to this the results of the research carried out by the SM-Walcz o Siebie Foundation entitled: "Contemporary diagnosis and treatment of MS in Poland", which shows that due to the lack of neurologists, the treatment initiation time is longer, we may face a serious systemic challenge.
